Please use this identifier to cite or link to this item:
Title: International Field Testing of the Reliability and Validity of the EORTC QLQ-BM22 Module to Assess Health-Related Quality of Life in Patients With Bone Metastases
Authors: Chow, Edward
Nguyen, Janet
Zhang, Liying
Tseng, Ling-Ming
Hou, Ming-Feng
Fairchild, Alysa
Vassiliou, Vassilios
Jesus-Garcia, Reynaldo [UNIFESP]
El-Din, Mohamed A. Alm
Kumar, Aswin
Forges, Fabien
Chie, Wei-Chu
Bottomley, Andrew
European Org Res Treatment Canc
Univ Toronto
Natl Yang Ming Univ
Kaohsiung Med Univ Hosp
Cross Canc Inst
Bank Cyprus Oncol Ctr
Universidade Federal de São Paulo (UNIFESP)
Tanta Univ Hosp
Reg Canc Ctr
St Etienne Univ Hosp
Natl Taiwan Univ
Eortc Data Ctr
Keywords: bone metastases
health-related quality of life
European Organization for Research and Treatment of Cancer (EORTC) QLQ-BM22
clinical trials
Issue Date: 1-Mar-2012
Publisher: Wiley-Blackwell
Citation: Cancer. Malden: Wiley-Blackwell, v. 118, n. 5, p. 1457-1465, 2012.
Abstract: BACKGROUND: the objective of this international field study was to test the reliability, validity, and responsiveness of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-BM22 module to assess health-related quality of life (HRQOL) in patients with bone metastases. METHODS: Patients undergoing a variety of bone metastases-specific treatments were accrued. the QLQ-BM22 was administered with the QLQ-C30 at baseline and at 1 follow-up time point internationally. A debriefing questionnaire was administered to determine patient acceptability and understanding. RESULTS: Large-scale field testing of the QLQ-BM22 in addition to the QLQ-C30 took place in 7 countries: Brazil, Canada, Cyprus, Egypt, France, India, and Taiwan. A total of 400 patients participated. Multitrait scaling analyses confirmed 4 scales in the 22-item module. the scales were able to discriminate between clinically distinct patient groups, such as between those with a poor and those with a better performance status. the QLQ-BM22 was well received in all 7 countries, and the majority of patients did not recommend any significant changes from the module in its current form. CONCLUSIONS: the final QLQ-BM22 module contains 22 items and 4 scales assessing Painful Sites, Painful Characteristics, Functional Interference, and Psychosocial Aspects. Results confirmed the validity, reliability, cross-cultural applicability, and sensitivity of the 22-item EORTC QLQ-BM22. It is therefore recommended that the QLQ-BM22 be used in addition to the QLQ-C30 in clinical trials to assess HRQOL in patients with bone metastases. (C) Cancer 2012; 118: 1457-65. (C) 2011 American Cancer Society.
ISSN: 0008-543X
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.